Skip to main content
Explore URMC
URMC / Research / Clinical Trials / Study Details

ASPIRE: Treating Children With Atopic Dermatitis (Eczema)

Research Question:
How do topical medications for atopic dermatitis affect health and quality of life in children and their caregivers?

Basic Study Information

Researchers are seeking to understand how two standard topical treatments for atopic dermatitis affect patient-reported outcomes (itch, pain, sleep, mood, and quality of life) and parent/caregiver quality of life. Participation will last approximately 12 weeks, which will include 3 clinic visits at UR Dermatology for clinical assessment of atopic dermatitis and the completion of electronic questionnaires by the child with atopic dermatitis and a parent/caregiver. Payment for participation is up to $130 if all visits are completed. You may be eligible if: You have a child between 2 to 15 years of age with a clinical diagnosis of mild to moderate Atopic Dermatitis. Your child does not have a diagnosis of another skin disease.

Location: University of Rochester Dermatology
Study Reference #: 00073062

Lead Researcher (Principal Investigator)

Lead Researcher:  Julie Wolf

Study Contact Information

Study Coordinator: Alicia Papilia
Phone: (585) 273-4195

Additional Study Details

Study Details:
This is an open-label, randomized, cross-sectional study to monitor the effects of crisaborole and tacrolimus 0.03% on patient-reported outcomes (PROs) and caregiver burden in children (ages 5 to 15 years, inclusive) with mild to moderate atopic dermatitis over a 12 week period of time. The goal of this study is to detect changes in PROs and caregiver burden during treatment for atopic dermatitis of moderate or less severity. The study design will allow us to correlate PROs and caregiver burden with treatment response and disease improvement in children. Children with mild to moderate atopic dermatitis (ages 5 to 15 years, inclusive) are eligible. Their parent or caregiver must also participate in the study with the child participant. The child will be randomized to tacrolimus 0.03% or crisaborole for their atopic dermatitis which they will use for 12 weeks. The study consists of 3 clinic visits over 12 weeks (baseline, 6 weeks, 12 weeks) during which the child's atopics dermatitis will be clinically assessed and the child and caregiver/parent will complete a questionnaire on an iPad. Subjects will be reimbursed for their participation in this study.

Number of Visits:  2 to 5
Parking:  Free
Transportation Coverage:  No
Reimbursement:  Yes
Payment Details:  Child participants will receive a $10 gift card at the end of each study visit for their participation. All adult caregiver subjects will be reimbursed $100 for completion of all study procedures. Payment will be prorated based on number of assessments completed in the study. Subjects will be paid $20 for completion of Baseline Assessment, $40 for completion of 6 Week Assessment, and $40 for completion of 12 Week Assessment. A check will be issued to the adult caregiver (i.e., caregiver) after completion of 12 Week Assessment or whenever their participation in the study has ended.

Learn More About These Conditions

More information about Dermatitis, Atopic

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search